The efficacy of anticancer therapies for advanced melanomas has been limited in the past, with an expected survival for patients on therapy of less than a year.1 However, the advent of immune checkpoint inhibitors (ICIs) and BRAF/MEK inhibitors has dramatically changed treatment outcomes.2-4 Currently, approximately 50% of patients with unresectable or metastatic cutaneous melanomas survive for more than 5 years.2 Genomic biomarkers that stratify responses to therapies have been extensively explored. The gene discussed is MAP2K7; the disease is melanoma.